Delpharm is a worldwide leader in contract manufacturing and development of medicines with : - 19 plants in France, Italy, Canada, Poland and The Netherlands - Over 1,1 billion euros turnover - Over 6,500 people - Most dosage forms produced For over 35 years, Delpharm has grown by progressively acquiring production plants, notably from major pharmaceutical laboratories. Today, Delpharm operates 18 industrial sites and 3 development centers located in France, Italy, Canada, the Netherlands, and Poland, producing over one billion boxes of medicines per year and contributing to the development of numerous projects. As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules. Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
| Website | http://www.delpharm.com/en/ |
| Revenue | $942.1 million |
| Employees | 3,922 (0 on RocketReach) |
| Phone | +33 1 41 09 19 70 |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Cdmo Services, Pharmaceutical Manufacturing, Dosage Forms, Contract Manufacturing, Pharmaceutical Production, Drug Development, Medicines Production, Drug Manufacturing, Drug Product Manufacturing, Clinical Trial Manufacturing, Drug Formulation, Pharmaceutical Packaging, Api Manufacturing, Sterile Manufacturing, Quality Control, Tablet Manufacturing, Capsule Manufacturing, Regulatory Affairs, Supply Chain |
| Competitors | Recipharm, FAREVA, Alcami Corporation, Aenova Group, Lonza, Siegfried Holding AG, Siegfried & Parzifal, Inc., Boehringer Ingelheim, Bristol Myers Squibb, NantPharma +44 more (view full list) |
Looking for a particular Delpharm employee's phone or email?
The Delpharm annual revenue was $942.1 million in 2026.